Eculizumab demonstrates its efficacy and safety in different populations of patients with paroxysmal nocturnal Paroxistica
Eculizumab demonstrates its efficacy and safety in different populations of patients with paroxysmal nocturnal Paroxistica in the seventeenth European Hematology Congress (EHA) – according to the results of different studies in different populations of patients with HPN, eculizumab inhibits the uncontrolled complement activation and intravascular hemolysis. Barcelona, July of 2012. Treatment with eculizumab demonstrates its efficacy and safety in different populations of patients who suffer from Hemoglobinuria Paroxistica night (HPN), a disease ultra-rara, progressive, which consists of uncontrolled complement system activation and that is life-threatening, as shown in studies presented at the seventeenth European Hematology Congress (EHA)held in Amsterdam. In this context, it should be noted between the communications presented at the Congress, the effectiveness of eculizumab in patients who, despite having a history of thrombosis, hemolysis was not severe enough to require blood transfusions. In fact, in a particular case that had suffered three major thrombotic crises for a period of five years, after the administration of eculizumab patient has not experienced relapse. Also, found a reduction of 86% of hemolysis with eculizumab in patients with HPN, valued by the LDH to 4.5 years. These data are very important since chronic complement-mediated hemolysis is the underlying cause of diseases associated with the HPN and its subsequent mortality. Patients with hemolysis 1.5 above the limit of normal (as measured by the LDH) at the time of the diagnosis had...
Read More